Results in a handful of patients raise hopes again for Curis's blood cancer project CA-4948, but it is still early days.
The success of previous forays into the clinical co-development space has enabled the UK venture firm to raise its biggest fund yet.
The company hopes that its novel approach in Friedreich’s ataxia could still have legs, but other assets are further ahead.
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
But financing sizes have grown by a similar amount on both sides of the Atlantic.
Large numbers of blank-cheque groups are seeking deals, but the bloom might be coming off the rose.
The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.